sign in sign up
<<
Home , Acetophenazine, Altrenogest, Amiodarone, Bolandiol, Captodiame, Chlormerodrin

TESTING STANDARDS AND PRACTICES PROGRAM.

Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0)

© ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019.

Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com

Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances

The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991.

"The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their , their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing , or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered. These drug classifications will be reviewed frequently and new drugs will be added when appropriate." Notes Regarding Classification Guidelines

• Where the use of a drug is specifically permitted by a jurisdiction, then the jurisdiction’s rule supersedes these penalty guidelines.

• Regulators should be aware that a laboratory report may identify a drug only by the name of its . The metabolite might not be listed here, but the parent compound may be.

• These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses.

• The facts of each case are different and there may be mitigating circumstances that should be considered.

• These drug classifications will be reviewed periodically. New drugs will be added or some drugs may be reclassified when appropriate.

• Racing Commissioners International (RCI) and/or the Racing Medication and Testing Consortium (RMTC) should be consulted for found substances or drugs not included in these guidelines and treated as Class 1 violations warranting a Class A penalty unless otherwise advised.

Page 2 of 66 Classification Criteria

The RCI Drug Classification Scheme is based on 1) pharmacology, 2) drug use patterns, and 3) the appropriateness of a drug for use in the racing horse. Categorization is decided using the following general guidelines:

• Pharmacology. Drugs that are known to be potent or are placed in higher classes, while those that have (or would be expected to have) little effect on the outcome of a race are placed in lower classes.

• Drug Use Patterns. Some consideration is given to placement of drugs based on practical experience with their use and the nature of positive tests. For example, positives have in the past been associated primarily with the administration of procaine , and this has been taken into consideration in the placement of procaine into Class 3 instead of Class 2 with other injectable local .

• Appropriateness of Drug Use. Drugs that clearly are intended for use in equine therapeutics are placed in lower classes. Drugs that clearly are not intended for use in the horse are placed in higher classes, particularly if they might affect the outcome of a race. Drugs that are recognized as legitimately useful in equine therapeutics but could affect the outcome of a race are placed in the middle or higher classes.

The list includes most drugs that have been reported as detected by racing authority laboratories in the , , the and other Association of Official Racing Chemists (AORC) laboratories, but does not include those which would seem to have no effect on the performance of the horse or drug detectability. For example, it does not include , sulfonamides, , anthelmintics, or pangamic , all of which have been reported.

The list contains many drugs that have never been reported as detected. Usually, these are representatives of chemical classes that have the potential for producing an effect, and in many cases, for which at least one drug in that chemical class has been reported.

Most drugs have numerous effects, and each was judged on an individual basis. There are instances where there is a rather fine distinction between drugs in one category and those in the next. This is a reflection of a nearly continuous spectrum of effects from the most innocuous drug on the list to the drug that is the most offensive.

Page 3 of 66 Classification Definitions

• Class 1: and drugs that have the highest potential to affect performance and that have no generally accepted medical use in the racing horse. Many of these agents are Drug Enforcement Agency (DEA) schedule II substances. These include the following drugs and their : , derivatives, synthetic and psychoactive drugs, and -like drugs as well as related drugs, including but not limited to , , , , and . Though not used as therapeutic agents, all DEA Schedule 1 agents are included in Class 1 because they are potent stimulant or depressant substances with psychotropic and often habituative actions. This class also includes all stimulating substances and their analogues.

• Class 2: Drugs that have a high potential to affect performance, but less of a potential than drugs in Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing , or 2) they are therapeutic agents that have a high potential for abuse. Drugs in this class include: psychotropic drugs, certain nervous system and cardiovascular system stimulants, depressants, and neuromuscular blocking agents. Injectable local anesthetics are included in this class because of their high potential for abuse as nerve blocking agents.

• Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2. Drugs in this class include , anabolic and other drugs with primary effects on the autonomic nervous system, procaine, with properties and the high-ceiling .

• Class 4: This class includes therapeutic that would be expected to have less potential to affect performance than those in Class 3. Drugs in this class includes less potent diuretics; ; antihistamines and relaxants without prominent (CNS) effects; expectorants and mucolytics; hemostatics; cardiac and anti-arrhythmics; topical anesthetics; antidiarrheals and mild . This class also includes the non-steroidal anti-inflammatory drugs (NSAIDs), at concentrations greater than established limits.

• Class 5: This class includes those therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain anti-allergic drugs. The drugs are also included.

Page 4 of 66 • Prohibited Practices:

A) The possession and/or use of a drug, substance or medication, specified below, on the premises of a facility under the jurisdiction of the regulatory body for which a recognized analytical method has not been developed to detect and confirm the administration of such substance; or the use of which may endanger the health and welfare of the horse or endanger the safety of the rider or driver; or the use of which may adversely affect the integrity of racing:

1) Erythropoietin 2) Darbepoetin 3) Oxyglobin 4) Hemopure

B) The possession and/or use of a drug, substance, or medication on the premises of a facility under the jurisdiction of the regulatory body that has not been approved by the United States Food and Drug Administration (FDA) for use in the United States.

C) The practice, administration, or application of a treatment, procedure, or method identified below, which is performed on the premises of a facility under jurisdiction of a regulatory body and which may endanger the health and welfare of the horse or endanger the safety of the rider or driver, or the use of which may adversely affect the integrity of racing:

Page 5 of 66 Drug Classification Scheme

• Class 1: Opiates, opium derivatives, synthetic opioids, psychoactive drugs, amphetamines, and all DEA Schedule I substances (see http://www.deadiversion.usdoj.gov/schedules/#list), and many DEA Schedule II drugs. Also found in this class are drugs that are potent stimulants of the CNS. Drugs in this class have no generally accepted medical use in the racing horse and their pharmacologic potential for altering the performance of a racing horse is very high. This class also includes all erythropoietin stimulating substances and their analogues.

• Class 2: Drugs placed in this category have a high potential for affecting the outcome of a race. Most are not generally accepted as therapeutic agents in the racing horse. Many are products intended to alter consciousness or the psychic state of humans, and have no approved or indicated use in the horse. Some, such as injectable local anesthetics, have legitimate use in equine , but should not be found in a racing horse. The following groups of drugs are placed in this class:

A. partial , or -antagonists. B. Non-opiate psychotropic drugs. These drugs may have stimulant, depressant, or neuroleptic effects. C. Miscellaneous drugs, which might have a stimulant effect on the CNS. D. Drugs with prominent CNS depressant action. E. Anti-depressant and drugs, with or without prominent CNS stimulatory or depressant effects. F. Muscle blocking drugs - those that have a direct neuromuscular blocking action. G. Local anesthetics that have a reasonable potential for use as nerve-blocking agents (except procaine). H. Snake and other biologic substances that may be used as nerve-blocking agents.

• Class 3: Drugs placed in this class may or may not have an accepted therapeutic use in the horse. Many are drugs that affect the cardiovascular, pulmonary and autonomic nervous systems. They all have the potential of affecting the performance of a racing horse. The following groups of drugs are placed in this class:

A. Drugs affecting the autonomic nervous system that do not have prominent CNS effects, but which do have prominent cardiovascular or respiratory system effects. Bronchodilators are included in this class. B. A local that has nerve-blocking potential but also has a high potential for producing residue levels from a method of use not related to the anesthetic effect of the drug (procaine). C. Miscellaneous drugs with mild sedative action, such as the sleep-inducing antihistamines. D. Primary vasodilating/hypotensive agents. E. Potent diuretics affecting renal function and body fluid composition. F. Anabolic and/or androgenic steroids and other drugs.

Page 6 of 66 • Class 4: Drugs in this category comprise primarily therapeutic medications routinely used in racehorses. These may influence performance, but generally have a more limited ability to do so. Groups of drugs assigned to this category include the following:

A. Non-opiate drugs that have a mild central antipyretic effect. B. Drugs affecting the autonomic nervous system that do not have prominent CNS, cardiovascular, or respiratory effects: 1. Drugs used solely as topical vasoconstrictors or . 2. Drugs used as gastrointestinal antispasmodics. 3. Drugs used to void the urinary bladder. 4. Drugs with a major effect on CNS vasculature or of visceral organs. C. Antihistamines that do not have a significant CNS depressant effect. This does not include the H2 blocking agents, which are in Class 5. D. drugs. E. Skeletal muscle relaxants. F. Anti-inflammatory drugs. These drugs may reduce pain as a consequence of their anti-inflammatory action. 1. Non-steroidal anti-inflammatory drugs (NSAIDs). (-like drugs). 2. Corticosteroids (). 3. Miscellaneous anti-inflammatory agents. G. Less potent diuretics. H. Cardiac glycosides and antiarrhythmic agents. 1. Cardiac glycosides. 2. Antiarrhythmic agents (exclusive of , , and ). 3. Miscellaneous cardiotonic drugs. I. Topical Anesthetics - agents not available in injectable formulations. J. Antidiarrheal drugs. K. Miscellaneous drugs: 1. Expectorants with little or no other pharmacologic action. 2. Stomachics. 3. Mucolytic agents.

• Class 5: Drugs in this category are therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain antiallergic drugs. The anticoagulant drugs are also included.

Page 7 of 66 UNIFORM CLASSIFICATION OF FOREIGN SUBSTANCES Version 14.0 (January, 2019) ALPHABETICAL SUBSTANCE LIST

© ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019.

Page 8 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class ∆-1-androstene-3, 17-diol 3 A ∆-1-androstene-3, 17-dione 3 A ∆-1- 3 A

1- (5a-androst-1- - endogenous weak steroid and 3 B intermediate in the of from Endogenous AAS ene-3β, 17β-diol) (DHEA) and of .

1- (5a-androst-1- Steroid - endogenous weak androgen and Endogenous AAS ene-3, 17-dione) 3 B intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.

1-testosterone (17β-hydroxy-5a- AAS lacking FDA 3 A Steroid - chemically related to anabolic steroids. androst-1-en-3-one) approval 19-Norandrostenediol 3 B 19-Norandrostenedione 3 B

Nandrolene Link - a metabolite of (19- B nortestosterone) and Metabolite of a B 19-noretiocholanolone. 3 substance bolandione (19-norandrostenedione).

2-Aminoheptane Tuamine 4 B 3-Methoxytyramine 3-MT 2 A 3,4- MDPV, “bath A methylenedioxypyprovalerone salts” 1

Hormone and Metabolic effects, same classification as 4-androstene-3,6,17 trione (6- has B 3 B Testolactone on Human Olympic Guidelines - classification oxo) inhibitors.

4-androstenediol (androst-4- Testosterone Link - androstenediol that is converted to Metabolized to a B 3 B ene-3β,17β-diol) testosterone. substance 4-Hydroxytestosterone 3 B

Page 9 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class 5-androstenedione (androst-5- Metabolized to a B 3 B Testosterone Link - prohormone of testosterone. ene-3,17-dione) substance Metabolite of a B 5α--3α,17α-diol 3 B Testosterone Link - testosterone metabolite. substance B Metabolite of a B 5α-androstane-3α,17β-diol 3 Testosterone Link - testosterone metabolite. substance B Testosterone Link - testosterone metabolite. Metabolite of a B 5α-androstane-3β,17α-diol 3 substance B Testosterone Link - testosterone metabolite. Metabolite of a B 5α-androstane-3β,17β-diol 3 substance 5β-androstane-3 α, 17β-diol, Testosterone Link - androstenediol that is converted to Metabolized to a B B androst-4-ene-3α,17α-diol 3 testosterone. substance

DHEA Link - a steroid produced by of the Metabolite of a B 7-keto-dhea;19- 3 B prohormone substance dehydroepiandrosterone (DHEA).

DHEA Link - naturally occurring steroid and a major Metabolite of a B 7α-hydroxy-dhea 3 B metabolite substance of dehydroepiandrosterone (DHEA).

DHEA Link - naturally occurring steroid and a major Metabolite of a B 7β-hydroxy-dhea 3 B metabolite substance of dehydroepiandrosterone (DHEA). a- 1 A Sectral 3 B 2 A Acenocoumarol 5 C Atrovet, Notensil, 3 B PromAce® Acetaminophen () Tylenol, Tempra, 4 C etc. Acetanilid 4 B Diamox, C Vetamox 4 Tindal 2 A

Page 10 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Acetophenetidin () 4 B Acetylsalicylic acid (Aspirin) 4 C

Activators of the AMP-activated protein kinase (AMPK) - E.g., PPARs are Hormone and Metabolic effects, same classification as AICAR, and Peroxisome AICAR A experimental drugs 2 Testolactone on Human Olympic Guidelines. Proliferator Activated δ without FDA approval (pparδ) agonists (e.g., GW 1516). 2 A monosemicarbazone salicylate 4 B Albuterol () Proventil, 3 B Ventolin NOTE: "A" penalty for quarter horse races. 2 B Aclovate 4 C Alcuronium Alloferin 2 A Aldocortin, 4 B Electrocortin Alfenta 1 A Axert 3 A Alphaprodine Nisentil 2 A Anaxyl 2 A Xanax 2 A 2 A Althesin Saffan 2 A

Altrenogest Regumate 4 C *Classification for geldings, colts, adult intact males only.

Ambenonium Mytelase, 3 B Myeuran Ambroxol Ambril, etc. 4 B Cyclocort 4 C Moduretic; 4 B Midamor Amicar, C Aminocaproic acid Caprocid 4

Page 11 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class

Hormone and Metabolic effects, same classification as Testolactone has B B 3 Testolactone on Human Olympic Guidelines. classification

Aminophylline Aminophyllin, 3 B etc. Aminopyrine 4 B Aminoxafen, Aminoxaphen, Apiquel, 1 A McN-742, Menocil 4 B Amisometradine Rolictron 4 B Solian 2 A Mitaban 3 B Elavil, Amitril, 2 A Endep Ammivin, B Norvasc 3 Amytal 2 A Asendin 2 A 2 A Amphetamine 1 A 4 B Amyl nitrite 2 A

Hormone and Metabolic effects, same classification as Testolactone has B 3 B Testolactone on Human Olympic Guidelines - Aromatase classification inhibitors.

Testosterone Link - an androstenediol that is converted to Metabolized to a B Androst-4-ene-3α,17β-diol B 3 testosterone. substance

Testosterone Link - an androstenediol that is converted to Metabolized to a B Androst-4-ene-3β,17α-diol B 3 testosterone. substance

Androst-5-ene-3α,17α-diol B Testosterone Link - androstenediol that is converted to Metabolized to a B 3 testosterone. substance

Page 12 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Metabolized to a B Androst-5-ene-3α,17β-diol 3 B Testosterone Link - prohormone of testosterone. substance

Metabolized to a B Androst-5-ene-3β,17α-diol 3 B Testosterone Link - prohormone of testosterone. substance

Hormone and Metabolic effects, same classification as Androsta-1,4,6-triene-3,17-dione Testolactone has B 3 B Testolactone on Human Olympic Guidelines - Aromatase (androstatrienedione) classification inhibitors.

Androstenediol (androst-5- Steroid: weak androgen and steroid hormone and B intermediate in the biosynthesis of testosterone from Metabolite of a B 3 substance ene-3β, 17β-diol) dehydropiandrosterone (DHEA)

Androstenedione (androst-4- Steroid: endogenous weak androgen steroid hormone and 3 B intermediate in the biosynthesis of testosterone from Endogenous AAS ene-3, 17-dione) dehydroepiandrosterone (DHEA) and of estrone.

Testosterone Link - a metabolite of testosterone and (3 β-hydroxy-5 α – Metabolite of a B 3 B dihydrotestosterone substance androstan-17-one) (DHT). Leritine 1 A Anisine 2 A Anisindione 5 D Anisotropine Valpin 4 B Antipyrine 4 B Apazone () Rheumox 4 B Apomorphine 1 A 4 B Alurate 2 A Erythropoietin Link - a nonerythropoietic engineered ARA-290 1 A from Blood doping agent erythropoietin.

Page 13 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class 3 A 3 B Aromatase inhibitors listed:

Articaine Septocaine; 2 B Ultracaine,

Erythropoietin Link - desialylated form of human glycoprotein hormone erythropoietin (EPO), which has been reported to be Asialo EPO A Blood doping agent 1 neuro-, cardio-, and renoprotective in animal models of organ .

Atenolol Tenormin 3 B Atipamazole 2 B Strattera 2 A Atracurium Tracrium 2 A 3 B Azacylonol Frenque 2 A Stresnil, Suicalm, Fentaz 2 A (with ) Lioresal 4 B Veronal 2 A 2 A Beclomethasone Propaderm 4 C Megimide, A Mikedimide 2 Lotrel, Lotensin 3 A Naturetin 4 B 2 B Benoxinate Dorsacaine 4 C Anquil 2 A Tiadipona 2 A Benzactizine Deprol, 2 A Bronchodiletten 4 B 2 A

Page 14 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class 2 A Tessalon, Benzonatate Tessalon Perles, 2 A Zonatuss Didrex 2 A Benzthiazide 4 B Benztropine Cogentin 2 A (BZP) 1 A Bepadin 4 B Betasone, etc. 4 C Kerlone 3 B Urecholine, 4 C Duvoid Esbatal 3 A Akineton 3 A Biriperone 2 A Zebeta, B Bisobloc, etc. 3 Effectin 3 A (estr-4-ene-3β, 17β- AAS lacking FDA A Steroid diol) 3 approval 3 A Equipoise 3 B 3 A Bretylium Bretylol 3 B Alphagan 2 A Lexotan, 2 A Lectopam Duract 3 A Bromhexine Oletor, etc. 4 B Bromisovalum Diffucord, etc. 2 A Parlodel 2 A Bromodiphenhydramine 3 B Bromidol 2 A Dimetane, 3 B Disomer Brotocol 2 A Pulmacort, 4 C Rhinocort

Page 15 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class 3 A Bumex 3 B Marcaine 2 A Temgesic 2 A Wellbutrin 2 A Buspar 2 A (Secbutobarbitone) Butacaps, 2 A Butasol, etc. Butyn 2 A () Fiorinal 2 A (butyl aminobenzoate) Butesin 4 C Hostacain 2 A Repoise 2 A Butoctamide Listomin 2 A Stadol, B Torbugesic 3 Butoxycaine Stadacain 4 B 2 B Methosorb 3 A Paxor 2 A 4 C Candesartan Atcand 3 B 1 Anti-epileptic, (CBD) analgesic 2 B Metabololite of a C substance - steroidal antimineralocorticoid, active metabolite of 4 C (a ). 2 B Covatine 2 A Captopril Capolen 3 B Carbacel, 3 A Conducton Lentin, Doryl 3 B Carbamezapine Tegretol 3 B Erythropoietin Link - may be a beneficial tissue-protective Carbamylated EPO A Blood doping agent 1 cytokine. Carbazochrome 4 B + levodopa Sinemet 2 A Clistin 3 B

Page 16 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Carbromol Mifudorm 2 A Cardarine (GW-501516) 2 A No legit use in the racehorse. Lacks FDA approval 1 A Rela, Soma 2 B Carphenazine Proketazine 2 A Prazinil 2 A Rimadyl 4 B Cartrol 3 B Carticaine (see ) Septocaine; 2 B Ultracaine, etc. Coreg 3 B khat, kat, qat, quat, chat, catha, 1 A Abyssinian tea, African tea Celebrex 3 B Zyrtec 4 C betaine Beta-Chlor 2 A Nactec, A Oridrate, etc. 2 Chloraldehyde (chloral) 2 A (Alpha-Chloralose) 2 A Librium 2 A Chlorhexidol 2 A Neohydrin 4 B Trancopal 2 A 2 A Chlorophenesin Maolate 4 C Nesacaine 2 A Chloroquine Avloclor 4 C Diuril 4 B Chlorpheniramine Chlortriemton, 4 B etc. Newiplege 2 A Thorazine, 1 A Largactil Taractan 2 A

Page 17 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Chlorthalidone Hydroton 4 B Paraflex 4 B Hormone and behavioral effects - a water soluble glycoprotein derived from human Chorionic (CG) urine. Used for behavior modification in colts / horses. There should be no restriction/regulation 3 B in fillies and . 4 C Pletal 4 B Cimeterol 3 A Tagamet 5 D Nupercaine 2 B Celex 2 A Clanobutin 4 B Tavist 3 B Ventipulmin 3 B NOTE: "A" penalty for quarter horse races. Clibucaine Batrax 2 A Clidinium Quarezan, 3 B Clindex, etc. Urbanyl 2 A Temovate 4 C 2 A Cloderm 4 C 4 B (Chlormethiazole) 2 A

Hormone and Metabolic effects, same classification as B Testolactone on Human Olympic Guidelines - Estrogen Testolactone has B Clomiphene 3 classification modulator.

Clomipramine Anafranil 2 A Klonopin 2 A Catapres 3 B Tranxene 2 A Clormecaine Placacid 2 A 3 A Clothiapine Entermin 2 A Trecalmo, Rize 2 A

Page 18 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Enadel, Sepazon, 2 A Tolestan Clozaril, 2 A Leponex

Erythropoietin Link - a biopharmaceutical consisting of a novel peptide that mimics the actions of erythropoietin, CNTO CNTO 530 A Blood doping agent 1 530 produced sustained increases in parameters.

For concentrations of less than 25 parts per billion (ppb) of blood serum or plasma no penalty is recommended. For concentrations of 25 ppb or greater but less than 50 ppb of blood B1 plasma or serum the recommended penalty is a written warning, the placement of the horse on the Cobalt (check note) 3 Veterinarians List with removal from list only after a blood test confirms that the concentration is below 25 ppb of or serum. Testing shall be paid by the owner(s) of the horse. Concentrations of 50 ppb or greater in blood plasma or serum have a recommended “B” penalty.

If it is determined by the State Veterinarian/Equine Medical Director; the Stewards, or the 1 A3 Racing Authority that the finding of cocaine or was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.

Codeine 1 A Colchicine 4 B Conorphone 2 A Corticaine Ultracain 2 A Corticotrophind 3 B Peptide hormone involved in the stress response. Cortone, etc. 4 C Cromolyn Intel 5 D Crotetamide 2 A Tercian 2 A Cyclandelate Cyclospasmol 3 A Merazine 3 B Phanodorm 2 A Flexeril 4 B

Page 19 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class

Hormone and Metabolic effects, same classification as Testolactone has B 3 B Testolactone on Human Olympic Guidelines - selective classification modulator (SERM).

Cyclomethycaine Surfacaine 4 C Anhydron, 4 B Renazide Pagitane 3 B Periactin 3 B Danocrine 3 B Dantrolene Dantrium 4 C Darbepoetin Aranesp 1 A

Erythropoietin Link - Bone marrow stimulant (Erythropoiesis- Darbepoetin (depo) 1 A stimulating agents are medications which stimulates the bone Blood doping agent marrow to make red blood cells).

Decamethonium Syncurine 2 A Dehydrochloromethyltestosteron A e 3 Dembroxol (Dembrexine) Sputolysin 4 C 2 A Percortin, DOCA, 4 C Deoxycorticosterone Descotone, Dorcostrin Deremaxx 3 B Dermorphin 1 A Norpromine, 2 A Pertofrane Des Owen 4 C Topicort 4 C 3 A Dormosedan 3 B

Page 20 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Azium, etc. 4 C 4 B Palfium, 1 A Narcolo Darvon 3 B Dalgan 2 A Diamorphine 1 A Valium 3 B Proglycem 3 B Dibucaine Nupercainal, 2 B Cinchocaine Febenol, Isocom 2 A Dichlorphenamide Daramide 4 C Voltaren, 4 C Voltarol Dicumarol Dicumarol 5 D Diethylpropion Tepanil, etc. 2 A Themalon 2 A Florone, C Maxiflor 4 Flu-Cortinest, 4 C etc. 3 B Crystodigin 4 B Lanoxin 4 B Parcodin 2 A 4 B Dihydrotestosterone (17β- Endogenous AAS hydroxy-5a-androstan-3-one) 3 B Steroid - endogenous androgen sex steroid and hormone. Dilorazepam Briantum 2 A Cardizem 4 B Dimefline 3 A Dimethisoquin Quotane 4 B Dimethylsulfoxide (DMSO) Domoso 4 C Diphenadione 5 C Benadryl 3 B , B Lomotil 4

Page 21 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class M50/50 2 A Persantine 3 B Dipyrone Novin, 4 B Methampyrone Norpace 4 B Divalproex Depakote 3 A Esucos 2 A Dobutrex 3 B Aricept 1 A Intropin 2 A Doxacurium Nuromax 2 A Doxapram Dopram 2 A 3 A Doxans 2 A Adapin, 2 A Sinequan Decapryn 3 B Dromostanolone Drolban 3 B Inapsine, Droleptan, A Innovar-Vet 2 (with Fentanyl) AAS lacking FDA 3 A Steroid approval 2 A Dyclonine Dyclone 4 C Dyphylline 3 B Edrophonium Tensilon 3 B Eletripan Relpax 3 A Eltenac 4 B (metabolite enaloprilat) Vasotec 3 A 2 A Endorphins 1 A 1 A 2 A

B Metabolite of a B Epi-dihydrotestosterone 3 Testosterone Link - androgenic metabolite of testosterone. substance 2 A

Page 22 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class 2 A

Testosterone Link - endogenous steroid and an epimer of the Endogenous, 3 B androgen sex stereoisomer of a hormone testosterone. B substance.

EPO-Fc 1 A Erythropoietin Link - fusion protein in human blood. Blood doping agent

EPO-mimetic (EMP): 1 A

Ergoloid mesylates ( mesylate, A mesylate, and 2 mesylate)

Ergonovine Ergotrate 4 C Gynergen, B Cafergot, etc. 4 Erthrityl tetranitrate Cardilate 3 A Epogen, Procrit, 1 A Erythropoietin (EPO) etc. Brevibloc 3 B Nexium 5 D Domnamid, Eurodin, 2 A Nuctalon 2 A Etacrynic acid 3 C 3 B Etanercept Enbrel 4 B Ethacrynic acid Edecrin 3 B Ethamivan 2 A 2 A Placidyl 2 A Valmid 2 A Zactane 2 A Ethopropazine Parsidol 2 A Zarontin 3 A

Page 23 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Peganone 4 B Cardrase, 4 C Ethamide Ethylaminobenzoate (Benzocaine) Semets, etc. 4 C Maxibolin, 3 B Organon Ethylisobutrazine Diquel 2 A Dionin 1 A Ethylnorepinephrine Bronkephrine 3 A 1 A Duranest 2 A Etifoxin Stresam 2 A

Testosterone Link - etiocholane steroid as well as an endogenous 17- that is produced from the B Metabolite of a B 3 metabolism of substance testosterone.

Etizolam Depas, Pasaden 2 A Lodine 3 B Indunox 2 A 2 A HCl M99 1 A

Hormone and Metabolic effects, same classification as Aromatase Testolactone has B inhibitors 3 B Testolactone on Human Olympic Guidelines - Aromatase classification inhibitors.

Famotidine Gaster, etc. 5 D Felbatol 3 B Plendil 4 B Fenarbamate Tymium 2 A Cincopal 3 B Myalex 2 B Pondimin 2 A Corlopam 3 B Nalfon 3 B Berotec 3 B

Page 24 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Respiride, 3 B Respan, etc Fentanyl Sublimaze 1 A 3 B Allegra 4 C

Fibroblast Growth Factors (fgfs), (HGF), - like Growth Factor-1 (IGF-1) and its analogues, Mechano Growth Factors (mgfs), -Derived Lack FDA approval; Growth Factor (PDGF), Vascular- Cardiac, Muscle effects - a family of peptide cytokines that are 3 A no legitimate use in Endothelial Growth Factor important in the regulation of many tissues. race horse. (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/ degradation, vascularization, energy utilization, regenerative capacity or fiber type switching.

Firocoxib 4 C Idalon 4 B Idalon, Idarac 4 B Sedalande 2 A Erispam 2 A Alforone, etc. 4 C 3 B Flumethasone Flucort, etc. 4 C Flumethiazide Ademol 4 B Sibelium 4 B Bronilide, etc. 4 C Rohypnol, Narcozep, A Darkene, 2 Hypnodorm Banamine 4 C*

Page 25 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Synalar 4 C Licon, Lidex 4 C Fluopromazine Psyquil, Siquil 2 A Fluoresone Caducid 2 A FML 4 C Fluoroprednisolone 4 B Prozac 2 A Halotestin 3 B Flupenthixol Depixol, 2 A Fluanxol Prolixin, Permitil, 2 B Anatensol, etc. Katadolone 3 A Alphadrol 4 C Flurandrenolide Cordran 4 C Dalmane 2 A Froben 3 B Imap, Redeptin 2 A Flixonase, C Flutide 4 Restas 2 A Dumirox, 2 A Faverin, etc. 3 A

Hormone and Metabolic effects, same classification as Aromatase Testolactone has B inhibitors 3 B Testolactone on Human Olympic Guidelines - Aromatase classification inhibitors.

Formoterol Altram 3 B Fosinopril Monopril 3 A Cerebyx 3 B

Hormone and Metabolic effects, same classification as Testolactone has B 3 B Testolactone on Human Olympic Guidelines - Estrogen classification antineoplastic agent.

Page 26 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class 3 A Lasix N/A Neurontin 3 B Reminyl 2 A Gallamine Flaxedil 2 A Gamma Aminobutryic Acid (GABA) Carolina Gold 3 B 2 A 3 A GH-Releasing Peptides (ghrps), e.g., alexamorelin, GHRP-6, Anabolic agent lacking 3 A Anabolic Effects - a synthetic GH secretagogue. FDA hexarelin and approval pralmorelin (GHRP-2) Doriden 2 A Glycopyrrolate Robinul 4 C

Growth Hormone Releasing Anabolic Effects - peptide analogue of growth hormone- Hormone (GHRH) and its releasing hormone which is used as a diagnostic agent to assess 3 A Anabolic agent lacking analogues, e.g., CJC- 1295, growth hormone secretion for the purpose of FDA approval sermorelin and tesamorelin diagnosing growth hormone deficiency.

Growth Hormone Secretagogues Anabolic agent lacking (GHS), e.g., ghrelin and ghrelin Anabolic Effects - hunger hormone, -enhancing and 3 A FDA mimetics, e.g., anabolic effects. approval anamorelin and ipamorelin

Guaifenesin ( guiacolate) Gecolate 4 C Wytensin 3 B Hylorel 3 A Ismelin 3 A Paxipam 2 A Halog 4 C Halobetasol Ultravate 4 C Haldol 2 A

Page 27 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Somelin 2 A Hemoglobin glutamers Oxyglobin 2 A Hemopure Corofundol 3 B 1 A Hexafluorenium Myalexen 2 A Evipal 2 A Tral 4 B Cyclaine 2 B

Cardiovascular Effects - a key mediator of oxygen homeostasis HIF activators (e.g. Argon, that was first identified as a factor that is induced 3 A Blood doping agent ) and activated by decreased oxygen tension.

Homatropine Homapin 3 B Homophenazine Pelvichthol 2 A Apresoline 3 B Hydrochlorthiazide Hydrodiuril 4 B (dihydrocodienone) Hycodan 1 A () Cortef, etc. 4 C Saluron 4 B Dilaudid 1 A Hydroxyamphetamine Paradrine 1 A Atarax 2 B Ibomal Noctal 2 A Motrin, Advil, 4 C Nurpin, etc. Corvert 3 B Ventavis 3 A Imavate, Presamine, 2 A Tofranil Diuretic 3 C Indomethacin Indocin 3 B Infliximab Remicade 4 B

Page 28 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Hormone and Metabolic effects, same classification as Testolactone on Human Olympic 3 B Guidelines - protein hormone that is used as a medication to treat high blood sugar. Ipratropium 3 B Irbesarten Avapro 3 A Isapirone 2 A Marplan 2 A Isoetharine Bronkosol 3 B Predef 2x 4 C 2 A Octin, Octon 4 B Darbid 4 B Isoproterenol Isoprel 2 A Isordil 3 B Maxicam 2 B Vasodilan 4 D DynaCirc 4 B 3 B Ketalar, Ketaset, B Vetalar 2 Anxon, Laftram, Solatran, 2 A Loftran Orudis 4 C* Toradol 3 A Normodyne 3 B Lamictal 3 A 5 D Elanone-V 2 A Viscotiol, 4 B Letosteine Visiotal 3 A 2 B Betagan 3 B 2 A Levo-Dremoran 1 A Lidocaine Xylocaine 2 B Lisinopril Prinivil, Zestril 3 A

Page 29 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Lithizine, 2 A Duralith, etc. 2 A 1 A Loflazepate, Ethyl Victan 2 A Imodium 3 B Dormonort, 2 A Havlane Loratidine Claritin 4 C Ativan 2 A Noctamid 2 A Hyzaar 3 B Laxitane 2 A Hormone and behavioral effects - a hormone produced by gonadotropic cells in the anterior (LH) B . In females, an acute rise of LH triggers and development of the corpus 3 luteum. Used for behavior modification in colts / horses. There should be no restriction/ regulation in fillies and mares. 3 A Ludiomil 2 A Mazindol Sanorex 1 A Axiten, A Dormate, Capla 2 Inversine 3 B Antivert, Bonine 3 B Arquel 4 C Lucidiril, etc. 2 A Nobrium, etc. 2 A Domitor 3 B Medriusar, etc. 4 C Ponstel 3 B Meldonium Mildronate, et 1 A al Mobic 4 B Eunerpan 2 A Namenda 2 A Meparfynol Oblivon 2 A Mepazine Pacatal 2 A Cantil 3 B

Page 30 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Meperidine Demerol 1 A Tolserol 4 B Control, etc. 2 A Wyamine 1 A Mesantoin 2 A Mephobarbital () Mebaral 2 A Carbocaine 2 B Equanil, 2 A Miltown Mercuhydrin 4 B Merbaphen Novasural 4 B Mercaptomerin Thiomerin 4 B Mercumatilin Cumertilin 4 B Salyrgan 4 B Mesalamine Asacol 5 C Serentil 2 A 3 A 3 A Talis 2 A AAS lacking FDA 3 A Steroid approval Alupent, 3 B Metaproterenol Metaprel Aramine 1 A Skelaxin 4 B 2 A AAS lacking FDA 3 A Steroid approval Metformin 2 B 3 A Dolophine 1 A Recommended Penalty B if testing can prove presence of only levo- Methamphetamine Desoxyn 1 A4 is present in sample. (Methylandrostenediol) Probolic 3 A Methandrostenolone Dianobal 3 A Banthine 3 B Histadyl, etc. 3 B

Page 31 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Quaalude 1 A Gemonil 2 A 3 A Methazolamide Naptazane 4 C 1 A Tacaryl 3 B Methenolone Primobolan 3 A Methixene Trest 3 A Robaxin 4 C Brevital 2 A Methotrexate Folex, Nexate, 4 B etc. Methotrimeprazine Levoprome, 2 A Neurocil, etc. Vasoxyl 3 A Orthoxide 3 A

Erythropoietin Link - an erythropoiesis-stimulating agent Methoxypolyethylene glycol- (ESA) indicated for the treatment of associated with A Blood doping agent epoetin beta (CERA) 1 chronic (CKD in adult patients on and patients not on dialysis.

Methscopolamine Pamine 4 B Methsuximide Celontin 4 B Enduron 4 B Methyl-1-testosterone 3 A 3 B 3 A Aldomet 3 A Methylergonovine Methergine 4 C Geranamine 1 A (Methylhexaneamine) Methylnortestosterone () 3 A Ritalin 1 A Medrol 4 C

Page 32 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Metandren 3 B Noludar 2 A Sansert 4 B 4 B Reglan 4 C Metubine 2 A 3 B Hypnodil 2 A (methydihydromorphinone) 1 A Lopressor 3 B A Steroid AAS lacking FDA 3 approval Melex 2 A Mexitil 4 B Posicor 3 B 3 B Versed 3 B Pro-Amiline 3 B 4 B Loniten 3 B Mirtazepine Remeron 2 A Cytotec 5 D Kratom 1 A Mivacurium Mivacron 2 A Provigil 2 A Moexipril (metabolite, Uniretic 3 B moexiprilat) Moban 2 A Elocon 4 C Singulair 4 C Luvatren 2 A

If it is determined by the State Veterinarian/Equine Medical Director; the Stewards, or the Morphine 1 A6 Racing Authority that the finding of cocaine or morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.

Page 33 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Mosaprimine 2 A 3 A myo-inositol trispyrophosphate (ITPP) 1 A N-Butylscopolamine 4 C Anthraxan, 3 A Relafen, Reliflex Nadol Corgard 3 B Naepaine Amylsine 2 A Nubain 2 A Nalline, 2 A Lethidrone Narcan 3 B Revia 3 B Nandrolin, Nandrolone Laurabolin, 3 B Durabolin Privine 4 B Equiproxen, 4 C Naprosyn Amerge 3 B 3 A Tilade 5 D Serzone 2 A 3 A Neostigmine Prostigmine 3 B Cardine 4 B Procardia 4 B Nifluril 3 B Nikethamide Coramine 1 A 3 B Erimin 2 A Nemotop 4 B Mogadon 2 A Nitroglycerin 2 B Axid 5 D

Page 34 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Nandrolene Link - a detectable metabolite of nandrolone, an Metabolite of a B Norandrosterone 3 B anabolic- substance androgenic steroid.

Norbolethone/ 3 A 3 A Nordiazepam Calmday, 2 A Nordaz, etc. 2 A 3 A Nortestosterone 3 B Aventyl, 2 A Pamelor Nylidrine Arlidin 3 A Olanzepine Zyprexa 2 A Olmesartan Benicar 3 A Olsalazine Dipentum 5 C Prilosec, Losec 5 D Norlfex 4 B 3 A Anavar 3 B Daypro, Deflam 4 B Serax 2 A Serenal 2 A Trileptal 3 A (hydroxyephedrine) 2 A Trasicor 3 A Percodan 1 A 3 A Afrin 4 B Adroyd, Anadrol 3 B Numorphan 1 A Oxyperitine Forit, Integrin 2 A Tandearil 4 C Daricon 4 B Oxyphenonium Antrenyl 4 B 2 A

Page 35 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Pancuronium Pavulon 2 A Protonix 5 D Pavagen, etc. 3 A Paral 2 A Paradione 3 A Haldrone 4 C Eutonyl 3 A Paxil, Seroxat 2 A

Erythropoietin Link - an erythropoiesis-stimulating agent Peginesatide 1 A (ESA) indicated for the treatment of anemia due to chronic Blood doping agent kidney disease (CKD) in adult patients on dialysis.

Pemoline Cylert 1 A Levatol 3 B Cyperon 2 A Pentaerythritol tetranitrate Duotrate 3 A Talwin 3 B Nembutal 2 A Trental, D Pentoxyfylline Vazofirin 4 Pentylenetetrazol Metrazol, Nioric 1 A Taxilan 2 A Perfluorocarbons 2 A Perfluorodecahydronophthalene 2 A Perfluorodecolin 2 A Perfluorooctylbromide 2 A Perfluorotripropylamine 2 A Permax 3 B Alodept, etc. 2 A Perindopril Biprel 3 A Hypnodin 2 A Trilafon 2 A Phenurone 4 B

Page 36 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Acalo, Alcamid, 2 A etc. Narphen 1 A (PCP) Sernylan 1 A Bontril, etc. 1 A Nardelzine, 2 A Nardil Phenindione Hedulin 5 D Preludin 1 A Luminal 2 A Dibenzyline 3 B Phenprocoumon Liquamar 5 D Milontin 4 B Iomamin 2 A Regitine 3 B Butazolidin 4 C* Isophrin, Neo- B 3 Propadrine 3 B Dilantin 4 B Physostigmine Eserine 3 A 1 A Alvodine, 2 A Cimadon 2 B Orap 2 A Domar 2 A Viskin 3 B Dipiperon 2 A Pipecuronium Arduan 2 A 2 A Psymod, Quide 2 A Metycaine 2 A Lonseren, 2 A Piportil Dataril, 2 A Gerondyl, etc. 2 A Maxair 3 B

Page 37 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Gastrozepin 5 C Arelix, Tauliz 3 B 1 A Feldene 4 B Plasma expanders (e.g. Bycerol; intravenous administration of albumin, dextran, 3 A No legit use in the racehorse. Lacks FDA approval. hydroxyethyl starch and ) Polyethylene glycol 5 D Renese 4 B Pramoxine Tronothaine 4 C (dehydroepiandrosterone, DHEA, 3 B Steroid - inactive endogenous steroid. Endogenous AAS 3β-hydroxyandrost-5-en-17-one)

Prazepam Verstran, 2 A Centrax Minipress 3 B Delta-Cortef, C etc. 4 Meticorten, etc. 4 C Citanest 2 B Mysoline 3 B 4 C Pronestyl 4 B Procaine 3 B Pro Air 3 A Darbazine, 2 A Compazine Kemadrin 3 B Sparine 3 B Phenergan 3 B Rythmol 4 B 2 A Propantheline Pro-Banthine 3 B Proparacaine Ophthaine 4 C Propentophylline Karsivan 3 B

Page 38 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Largon 2 A Propionylpromazine Tranvet 2 A 2 A Diprivan, 2 A Disoprivan Ravocaine 2 A Propranolol Inderal 3 B Benzedrex 4 B Prostanazol 3 A Dominal 2 A Ventaire 3 A Concordin, 2 A Triptil Axeen, 2 A Centralgol Cenafed, B Novafed 3 Mestinon, B Pyridostigmine Regonol 3 Neoantergan, 3 B Pyrilamine Equihist Hybersulfan, 2 A Sonodor Quazipam Doral 2 A Seroquel 2 A Quinapril, Quinaprilat Accupril 3 A 3 A Quinidex, 4 B Quinicardine Aciphex 5 D Racemethorphan 2 A 2 A 2 A Paylean 2 A

Estrogen effects, same classification as Testolactone on Human B Olympic Guidelines - selective estrogen receptor modulators- Testolactone has B 3 classification SERMs.

Page 39 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Ramipril, metabolite Ramiprilat Altace 3 A Zantac 5 D Ultiva 1 A Roxiam 2 A Serpasil 2 B 2 A 2 A 2 A Yutopar 3 B Rivastigmine Exelon 2 A Maxalt 3 B Rocuronium Zemuron 2 A Vioxx 2 B Sedivet 3 B Naropin 2 A

Erythropoietin Link - HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, A Blood doping agent Roxadustat (FG-4592) 1 which stimulates production of hemoglobin and red blood cells.

Salicylamide 4 C Salicylate 4 C 3 B (Hyoscine) Triptone 4 C (Quinalbarbitone) Seconal 2 A Eldepryl, 2 A Jumex, etc. Lustral, Zoloft 2 A Meridia 3 B Viagra 3 A Snake Venoms 1 A Somatrem Protropin 2 A Somatropin Nutropin 2 A

Page 40 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Betapace, 3 B Sotacor Spiclomazine 2 A 2 A Spirapril, metabolite Spiraprilat Renomax 3 A Spironalactone Aldactone 4 B Spironolactone Diuretic 3 C Winstrol-V 3 B 3 A 1 A Succinylcholine Sucostrin, 2 A Quelin, etc. Sufenta 1 A Azulfidine, C Azaline 4 Sulfondiethylmethane 2 A 2 A Inofal 2 A Clinoril 3 B Aiglonyl, 2 A Sulpitil Barnetil 2 A Imitrex 3 B Synthetic Spice, K2, 1 A Kronic Tadalasil Cialis 3 A Talbutal Lotusate 2 A

Hormone and Metabolic effects, same classification as Testolactone has B 3 B Testolactone on Human Olympic Guidelines - Estrogen classification receptor antagonist antineoplastic agent.

Tandospirone 2 A TCO2 3 B Telmisartin Micardis 3 B Restoril 2 A Alganex, etc. 3 B

Page 41 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class 3 B Hytrin 3 A Brethine, 3 B Bricanyl Seldane, 4 C Triludan Testolactone Teslac 3 B Testosterone 3 B Nitoman 2 A Pontocaine 2 A 3 A Tetrahydrozoline Tyzine 4 B Musaril, 2 A Myolastin 2 Drug of human A Drug of human abuse. THC () abuse 1 2 A 4 B Aqualphyllin, 3 B etc. Kemithal 2 A Surital 2 A Torecan 2 A Thiopental Pentothal 2 A Dartal 2 A Majeptil 2 A Mellaril 2 A Thiosalicylate 4 B Thiothixene Navane 2 A Thiphenamil Trocinate 4 B Thyroxine and modulators/, including but not limited to those containing T4 3 C FDA approvad but has (limited) legitimate use in care of racehorses. (tetraiodothyronine/thyroxine), T3 (), or combinations thereof. Italprid, 2 A Luxoben, etc.

Page 42 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Surgam 3 B AAS lacking FDA 3 A Steroid - synthetic steroid. approval Component of 2 A Telazol Tolopelon 2 A Blocardrin 3 B Tonocard 4 B Grandaxain, 2 A Seriel Priscoline 3 B 4 B Tolectin 3 B Topirimate Topamax 2 A B Hormone and Metabolic effects, same classification as Testolactone on Human Olympic 3 Guidelines - Selective estrogen . Torsemide () Demadex 3 A Ultram 2 B Trandolapril (and metabolite, Tarka B trandolaprilat) 3 Tranexamic acid 4 C Parnate 2 A Desyrel 2 A Finoplix 3 B Inolin 2 A Vetalog, etc. 4 C Dyrenium 4 B Halcion 2 A Tribromethanol 2 A Tricaine methanesulfonate Finquel 2 A Naqua, 4 C Naquasone Trichloroethanol 2 A Tricholoethylene Trilene, Trimar 2 A Triclos 2 A Pathilon 4 B Trifluomeprazine Nortran 2 A

Page 43 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Stelazine 2 A Triperidol 2 A Vetame, Vesprin 2 A Trihexylphenidyl Artane 3 A Trimeprazine Temaril 4 B Hormone and Metabolic effects, same classification as Testolactone on Human Olympic 3 B Guidelines - a drug for pectoris, the first cytoprotective anti- ischemic agent. Tridione 3 B Trimethaphan Arfonad 3 A Surmontil 2 A PBZ 3 B Actidil 3 B Tubocurarine () Metubin 2 A Benvil, Nospan, 2 A etc. Urethane 2 A 2 B 3 A Nirvanyl 2 A Diovan 3 B Levitra 3 A 4 B Efflexor 2 A Accional, 2 A Veralipril Calan, Isoptin 4 B Vercuronium Norcuron 2 A Catatrol, 2 A Vivalan, etc. Delvinol 2 A Optanox, Speda 2 A Coumadin, 5 D Coufarin Rompun, Bay Va 3 B 1470 Otrivin 4 B 2 B Accolate 4 C

Page 44 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class Sonata 2 A Ralgro 4 C 1 A Zyflo 4 C hydrochloride Zilpaterol 2 A Geoden 2 A 2 A Zomig 3 B Ambien, Stilnox 2 A Zomax 2 B Zonegran 3 B Imovan 2 A Lodopin 2 A Ciatyl, 2 A Cesordinol

Page 45 of 66 ARCI Uniform Classification of Substances - Version 14.0 - January, 2019

Trade Drug Penalty Class Special Notation Note. Drug/Substance Name(s) Class

Page 46 of 66 Non-Classified Substances

Aminoglycosides

Benzimadaziles

NOTE: Dimethylsulphone (MSM) has been removed from the classification document and its status is “Do Not Report”.

Page 47 of 66 UNIFORM CLASSIFICATION OF FOREIGN SUBSTANCES Version 14.0 PENALTY GUIDELINES

Ó ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019.

Association of Racing Commissioners International 1510 Newtown Pike, Lexington, Kentucky, United States www.arci.com

Page 48 of 66 PENALTY CATEGORY “A”

The following are recommended penalties for violations due to the presence of a drug carrying a Category “A” penalty and for violations of ARCI-011-015 and ARCI-025-015: Prohibited Practices:

LICENSED TRAINER: 1st Offense 2nd LIFETIME offense in any jurisdiction 3rd LIFETIME offense in any jurisdiction • Minimum one-year suspension absent mitigating • Minimum three-year suspension absent mitigating • Minimum five-year suspension absent mitigating circumstances. The presence of aggravating factors circumstances. The presence of aggravating factors circumstances. The presence of aggravating factors could be used to impose a maximum of a three-year could be used to impose a maximum of license could be used to impose a maximum of license suspension revocation with no reapplication for a three-year revocation with no reapplication for a five-year period. period.

AND AND AND • Minimum fine of $10,000 or 10% of total purse • Minimum fine of $25,000 or 25% of total purse • Minimum fine of $50,000 or 50% of total purse (greater of the two) absent mitigating circumstances. (greater of the two) absent mitigating circumstances. (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used The presence of aggravating factors could be used to The preence of aggravating factors could be used to to impose a maximum of $25,000 or 25% of purse impose a maximum of $50,000 or 50% purse impose a maximum of $100,000 or 100% purse (greater of the two). (greater of the two). (greater of the two).

AND AND AND • May be referred to the Commission for any further • May be referred to the Commission for any further • May be referred to the Commission for any further action deemed necessary by the Commission. action deemed necessary by the Commission. action deemed necessary by the Commission. LICENSED OWNER: nd rd st 2 LIFETIME offense in owner’s stable any 3 LIFETIME offense in owner’s stable in any 1 Offense jurisdiction jurisdiction • Disqualification and loss of purse • Disqualification and loss of purse • Disqualification, loss of purse and $50,000 fine AND AND AND • Horse shall be placed on the Veterinarian’s List for • Horse shall be placed on the Veterinarian’s List for • Horse shall be placed on the Veterinarian’s List for 180 days and must pass a commission-approved 180 days and must pass a commission-approved 180 days and must pass a commission-approved examination before becoming eligible to be entered. examination before becoming eligible to be entered. examination before becoming eligible to be entered. AND • Referral to the Commission with a recommendation of a suspension for a minimum of 90 days.

Page 49 of 66 PENALTY CATEGORY “B”

The following are recommended penalties for violations due to the presence of a drug carrying Category “B” penalty, for the presence of more than one NSAID a plasma/serum sample, subject to the provisions set forth in ARCI-011-020(E) and ARCI-025-020(E) and for violations of the established levels for total carbon dioxide:

LICENSED TRAINER: 1st Offense 2nd offense (365-day period) in any jurisdiction 3rd offense (365-day period) in any jurisdiction • Minimum 15-day suspension absent mitigating • Minimum 30-day suspension absent mitigating • Minimum 60-day suspension absent mitigating circumstances. The presence of aggravating factors circumstances. The presence of aggravating factors circumstances. The presence of aggravating factors could be used to impose a maximum of a 60-day could be used to impose a maximum of a 180-day could be used to impose a maximum of a one-year suspension suspension suspension.

AND AND • Minimum fine of $500 absent mitigating • Minimum fine of $1,000 absent mitigating • Minimum fine of $2,500 absent mitigating circumstances. The presence of aggravating factors circumstances. The presence of aggravating factors circumstances. The presence of aggravating factors could be used to impose a maximum fine of $1,000. could be used to impose a maximum fine of $2,500. could be used to impose a maximum of $5,000 or 5% purse (greater of the two).

AND • May be referred to the Commission for any further action deemed necessary by the Commission. LICENSED OWNER: nd rd st 2 offense (365-day period) in owner’s stable any 3 offense (365-day period) in owner’s stable in any 1 Offense jurisdiction jurisdiction • Disqualification and loss of purse [in the absence of • Disqualification and loss of purse [in the absence of • Disqualification, loss of purse, and in the absence of mitigating circumstances]* mitigating circumstances]* mitigating circumstances a $5,000 fine.* AND AND AND • Horse must pass a commission-approved • Horse must pass a commission-approved • Horse shall be placed on the Veterinarian’s List for examination before becoming eligible to be entered. examination before becoming eligible to be entered. 45 days and must pass a commission-approved examination before becoming eligible to be entered.

Page 50 of 66 PENALTY CATEGORY “C”

The following are recommended penalties for violations due to the presence of a drug carrying a Category “C” penalty and overages for permitted NSAIDs and furosemide: (All concentrations are for measurements in serum or plasma.)

Phenylbutazone (>2.0-5.0 mcg/ml)* Phenylbutazone (>5.0 mcg/ml) Flunixin (>20 - 100 ng/ml) Flunxin (>100 ng/ml) LICENSED TRAINER Ketoprofen (>2- 50 ng/ml) Ketoprofen (>50 ng/ml) and Furosemide (>100 ng/ml) and/or CLASS C Violations no furosemide when identified as administered 1st Offense (365-day period) in any Minimum of a written warning to maximum fine of Minimum fine of $1,000 absent mitigating circumstances jurisdiction $500

2nd Offense (365-day period) in any Minimum of a written warning to maximum fine of Minimum fine of $1,500 and 15-day suspension absent mitigating jurisdiction $750 circumstances

3rd Offense (365-day period) in any Minimum fine of $500 to a maximum fine of $1,000 Minimum fine of $2,500 and 30-day suspension absent mitigating jurisdiction circumstances

Phenylbutazone (>2.0-5.0 mcg/ml)* Phenylbutazone (>5.0 mcg/ml) Flunixin (>20 - 100 ng/ml) Flunxin (>100 ng/ml) LICENSED OWNER Ketoprofen (>2- 50 ng/ml) Ketoprofen (>50 ng/ml) and Furosemide (>100 ng/ml) and/or CLASS C Violations no furosemide when identified as administered 1st Offense (365-day period) in any Horse may be required to pass commission-approved Disqualification and loss of purse in the absence of mitigating jurisdiction examination before being eligible to run circumstances. Horse must pass commission-approved examination before being eligible to run. 2nd Offense (365-day period) in any Horse may be required to pass commission-approved Disqualification and loss of purse in the absence of mitigating jurisdiction examination before being eligible to run circumstances. If same horse, placed on veterinarian’s list for 45 days, must pass commission-approved examination before being eligible to run 3rd Offense (365-day period) in any Disqualification and loss of purse. Horse must pass Disqualification and loss of purse in the absence of mitigating jurisdiction commission-approved examination before being eligible circumstances. Minimum $5,000 fine. If same horse, placed on to run veterinarian’s list for 60 days, must pass commission-approved examination before being eligible to run

*If the trainer has not had more than one violation within the previous two years, the Stewards/Judges are encouraged to issue a warning in lieu of a fine provided the reported level is below 3.0 mcg/ml absent of aggravating factors.

After a two-year period, if the licensee has had no further violations, any penalty due to an overage in the 2.0-5.0 category will be expunged from the licensee’s record for penalty purposes.

Page 51 of 66 PENALTY CATEGORY “D”

The recommended penalty for a violation involving a drug that carries a Category “D” penalty is a written warning to the trainer and owner. Multiple violations may result in fines and/or suspension.

Page 52 of 66 MMV Point System Multiple Medication Violation Model Rule. ARCI-011-020 (B)(13)

Officials are advised to check a licensee’s ARCI regulatory record to see if multiple medication violations should be considered as an aggravating factor in the determination of an appropriate penalty.

(1) Multiple Medication Violations (MMV) (a) A trainer who receives a penalty for a medication violation based upon a horse testing positive for a Class 1-5 medication with Penalty Class A-C, as provided in the most recent version of the ARCI Uniform Classification Guidelines for Foreign Substances, or similar state regulatory guidelines, shall be assigned points as follows:

Points If Controlled Points If Non-Controlled Penalty Class Therapeutic Substance Substance Class A N/A 6 Class B 2 4 ½ for first violation with 1 for first violation with an additional ½ point for an additional ½ point for Class C each additional violation each additional violation within 365 days1 within 365 days Class D 0 0 1 Points for NSAID violations only apply when the primary threshold of the NSAID is exceeded. Points are not to be separately assigned for a stacking violation.

If the Stewards or Commission determine that the violation is due to environmental contamination, they may assign lesser or no points against the trainer based upon the specific facts of the case.

(b) The points assigned to a medication violation by the Stewards or Commission ruling shall be included in the ARCI official database. The ARCI shall record points consistent with Section 13(a) including when appropriate, a designation that points have been suspended for the medication violation. Points assigned by such regulatory ruling shall reflect, in the case of multiple positive tests as described in paragraph

Page 53 of 66 (d), whether they constitute a single violation. The Stewards’ or Commission Ruling shall be posted on the official website of the Commission and within the official database of the Association of Racing Commissioners International. If an appeal is pending, that fact shall be noted in such Ruling. No points shall be applied until a final adjudication of the enforcement of any such violation.

(c) A trainer’s cumulative points for violations in all racing jurisdictions shall be maintained by the ARCI. Once all appeals are waived or exhausted, the points shall immediately become part of the trainer’s official ARCI record and shall be considered by the Commission in its determination to subject the trainer to the mandatory enhanced penalties by the Stewards or Commission as provided in this regulation.

(d) Multiple positive tests for the same medication incurred by a trainer prior to delivery of official notice by the commission may be treated as a single violation. In the case of a positive test indicating multiple substances found in a single post-race sample, the Stewards may treat each substance found as an individual violation for which points will be assigned, depending upon the facts and circumstances of the case.

(e) The official ARCI record shall be used to advise the Stewards or Commission of a trainer’s past record of violations and cumulative points. Nothing in this administrative regulation shall be construed to confer upon a licensed trainer the right to appeal a violation for which all remedies have been exhausted or for which the appeal time has expired as provided by applicable law.

(f) The Stewards or Commission shall consider all points for violations in all racing jurisdictions as contained in the trainer’s official ARCI record when determining whether the mandatory enhancements provided in this regulation shall be imposed.

(g) In addition to the penalty for the underlying offense, the following enhancements shall be imposed upon a licensed trainer based upon the cumulative points contained in his/her official ARCI record:

Points Suspension in days 5-5.5 15 to 30 6-8.5 30 to 60 9-10.5 90 to 180 11 or more 180 to 360

MMV penalties are not a substitute for the current penalty system and are intended to be an additional uniform penalty when the licensee: (i) Has had more than one medication violation for the relevant time period, and (ii) Exceeds the permissible number of points.

Page 54 of 66 The Stewards and Commission shall consider aggravating and mitigating circumstances, including the trainer’s prior record for medication violations, when determining the appropriate penalty for the underlying offense. The MMP is intended to be a separate and additional penalty for a pattern of violations.

(h) The suspension periods as provided in Section 13(g) shall run consecutive to any suspension imposed for the underlying offense.

(i) The Stewards’ or Commission Ruling shall distinguish between the penalty for the underlying offense and any enhancement based upon a Stewards or Commission review of the trainer’s cumulative points and regulatory record, which may be considered an aggravating factor in a case.

(j) Points shall expire as follows:

Penalty Classification Time to Expire A 3 years B 2 years C 1 year

In the case of a medication violation that results in a suspension, any points assessed expire on the anniversary date of the date the suspension is completed.

Page 55 of 66 NSAID STACKING MODEL RULE ARCI-011-020 (E)

E. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (1) The use of NSAIDs shall be governed by the following conditions: (a) (BLANK) (b) NSAIDs included in the ARCI Controlled Therapeutic Medication Schedule, Version 2.2, are not to be used in a manner inconsistent with the restrictions contained therein. NSAIDs not included on the ARCI Controlled Therapeutic Medication Schedule, Version 2.2, are not be present in a racing horse biological sample at the laboratory concentration of detection. (c) The presence of more than one NSAID may constitute a NSAID stacking violation consistent with the following restrictions: A. A Class 1 NSAID Stacking Violation (Penalty Class B) occurs when: i. Two non-steroidal anti-inflammatory drugs are found at individual levels determined to exceed the following restrictions: a. Diclofenac – 5 nanograms per milliliter of plasma or serum; b. - 20 nanograms per milliliter of plasma or serum; c. Flunixin – 20 nanograms per milliliter of plasma or serum; d. Ketoprofen – 2 nanograms per milliliter of plasma or serum; e. Phenylbutazone – 2 micrograms per milliliter of plasma or serum; or f. all other non-steroidal anti-inflammatory drugs – laboratory concentration of detection ii. Three or more non-steroidal anti-inflammatory drugs are found at individual levels determined to exceed the following restrictions: a. Diclofenac – 5 nanograms per milliliter of plasma or serum; b. Firocoxib - 20 nanograms per milliliter of plasma or serum; c. Flunixin – 3 nanograms per milliliter of plasma or serum; d. Ketoprofen – 1 nanograms per milliliter of plasma or serum; e. Phenylbutazone – 0.3 micrograms per milliliter of plasma or serum; or f. all other non-steroidal anti-inflammatory drugs – laboratory concentration of detection.

Page 56 of 66 B. A Class 2 NSAID Stacking Violation (Penalty Class C) occurs when: i. Any one substance noted in Subsection (A)(i) above is found in excess of the restrictions contained therein in combination with any one of the following substances at levels below the restrictions so noted but in excess of the following levels: a. Flunixin – 3 nanograms per milliliter of plasma or serum; b. Ketoprofen – 1 nanogram per milliliter of plasma or serum; or c. Phenylbutazone – 0.3 micrograms per milliliter of plasma or serum;

C. A Class 3 NSAID Stacking Violation (Penalty Class C, fines only) occurs when: i. Any combination of two of the following non-steroidal anti-inflammatory drugs are found at or below the restrictions in Subsection (A)(i)(a through e) above but in excess of the noted restrictions: a. Flunixin – 3 nanograms per milliliter of plasma or serum; b. Ketoprofen – 1 nanogram per milliliter of plasma or serum; or c. Phenylbutazone – 0.3 micrograms per milliliter of plasma or serum;

(2) Any horse to which a NSAID has been administered shall be subject to having a blood and/or urine sample(s) taken at the direction of the official veterinarian to determine the quantitative NSAID level(s) and/or the presence of other drugs which may be present in the blood or urine sample(s).

Page 57 of 66 Recent Document Revisions

Version Dat Drug/Substance Notes e 13.4.1 August 2018 Added a missing footnote. 13.4 January 2018 Dipyrone Penalty Classification changed from C to B; remains 4 13.4 January 2018 Tolfenamic Acid Added as Drug Class 4, Penalty Class B 13.4 January 2018 Pimobendan Added as Drug Class 2, Penalty Class B 13.4 January 2018 Mitragynine Added as Drug Class 1, Penalty Class A 13.4 January 2018 Metformin Added as Drug Class 2, Penalty Class B 13.4 January 2018 Letrozole Added as Drug Class 3, Penalty Class A 13.4 January 2018 Capsaicin Added as Drug Class 2, Penalty Class B 13.4 January 2018 Altrenogest Added as Drug Class 4, Penalty Class C in male horses only; no restriction in female horses. 13.3 July 2017 Penalty C Guideline Modification Added “[in the absence of mitigating circumstances]” for owner 1st offense 13.2 April 2017 Pemalty A Guideline Modification Increase time on vets list to 180 days

13.2 April 2017 Articaine, Carticaine, and Priolocaine Penalty Class Changed from A to B 13.2 April 2017 Cinchocaine Penalty Class Changed from A to B 13.2 April 2017 Formebolone Penalty Class Change from B to A 13.2 April 2017 Methyltestosterone Penalty Class Change from A to B 13.2 April 2017 Methyl-1-testosterone Added; Class 3, Penalty Class A 13.2 April 2017 Oxymesterone Penalty Class Change from B to A 13.2 April 2017 Sulindac Penalty Class Change from A to B 13.2 April 2017 Valdecoxib Penalty Change from A to B 13.2 April 2017 Benazepril Penalty Class Changed to A 13.2 April 2017 Eszopiclone Added Class 2; Penalty Class A 13.2 April 2017 Propantheline Penalty Class B assigned. 13.00 January 11, Version 13.00 Publication Date 2017 13.00 December Methdilazine Changed from Class 4 to Class 3 2016 13.00 December Naepaine Changed from Class 4/Penalty C to Class 2/Penalty A 2016 13.00 December Nortestosterone Changed from Class 4/Penalty C to Class 3/Penalty B

Page 58 of 66 2016 13.00 December Olsalazine Changed from Class 4/Penalty B to Class 5/Penalty C 2016 13.00 December Oxaprozin Changed from Penalty C to Penalty B 2016 13.00 December Pentoxyfylline Changed from Penalty C to Penalty D 2016 13.00 December Terfenadine Changed from Penalty B to Penalty C 2016 13.00 December Thiosalicylate Changed from Penalty C to Penalty B 2016 13.00 December Triprolidine Changed from Class 4 to Class 3 2016 13.00 December Anisindione Changed from Penalty C to Penalty D 2016 13.00 December Cilostazol Changed from Class 5/Penalty C to Class 4/Penalty B 2016 13.00 December Cromolyn Changed from Penalty C to Penalty D 2016 13.00 December Dimethylsulphone (MSM) Removed from classifications; recommended “do not report” 2016 13.00 December Misoprostol Changed from Penalty C to Penalty D 2016 13.00 December Nedocromil Changed from Penalty C to Penalty D 2016 13.00 December Phenindione Changed from Penalty C to Penalty D 2016

Page 59 of 66 Approx. Version Date Drug/Substance Notes Page(s) 13.00 December 2016 Phenprocoumon Changed from Penalty C to Penalty D 9, 26 13.00 December 2016 Polyethylene Glycol Changed from Penalty C to Penalty D 9, 26 13.00 December 2016 Warfarin Changed from Penalty C to Penalty D 11, 26 13.00 December 2016 Pirbuterol Changed from Penalty A to Penalty B 9, 21 13.00 December 2016 Piroxicam Changed from Class 3 to Class 4 9, 24 13.00 December 2016 Prostanazol Changed from Penalty B to Penalty A 9, 21 13.00 December 2016 Quinbolone Changed from Penalty B to Penalty A 9, 21 13.00 December 2016 Scopolamine Changed from Class 3/Penalty B to Class 4/Penalty C 10, 25 13.00 December 2016 Stenbolone Changed from Penalty B to Penalty A 10, 22 Changed from Unclassified with Penalty B recommended to 13.00 December 2016 TCO2 Class 3/Penalty B 10, 22 13.00 December 2016 Acetazolamide Changed from Penalty B to Penalty C 1, 23 13.00 December 2016 Ambroxol Changed from Penalty C to Penalty B 1, 23 13.01 December 2016 Cocaine and Morphine Added a footnote inadvertently excluded from V.13.0 13.00 December 2016 Brompheniramine Changed from Class 4 to Class 3 2, 19 13.00 December 2016 Butacaine Changed from Class 4/Penalty C to Class 2/Penalty A 2, 14 13.00 December 2016 Carbazochrome Changed from Penalty C to Penalty B 2, 23 13.00 December 2016 Ciclesonide Changed from Penalty B to Penalty C 3, 23 3,4,14, 13.00 December 2016 Cinchocaine Changed from Class 4/Penalty C to Class 2/Penalty A 15 13.00 December 2016 Clibucaine Changed from Class 4/Penalty C to Class 2/Penalty A 3,15 13.00 December 2016 Clormecaine Changed from Class 4/Penalty C to Class 2/Penalty A 3,15 13.00 December 2016 Cyclizine Changed from Class 4 to Class 3 3,19 13.00 December 2016 Cyproheptadine Changed from Class 4/Penalty C to Class 3/Penalty B 3,19 13.00 December 2016 Dibucaine Changed from Class 4/Penalty C to Class 2/Penalty B 4,15 13.00 December 2016 Eltenac Changed from Penalty C to Penalty B 4,23 13.00 December 2016 Ethoheptazine Changed from Class 4/Penalty C to Class 2/Penalty A 4,15 13.00 December 2016 Fluorometholone Changed from Penalty B to Penalty C 5,24 13.00 December 2016 Fluoroprednisolone Changed from Penalty C to Penalty B 5,24 13.00 December 2016 Hexylcaine Changed from Class 4/Penalty C to Class 2/Penalty B 5,16 13.00 December 2016 Isoxsuprine Changed from Penalty C to Penalty D 6,24 13.00 December 2016 Letosteine Changed from Penalty C to Penalty B 6,24

Page 60 of 66 Approx. Version Date Drug/Substance Notes Page(s) 13.00 December 2016 Loratidine Changed from Penalty B to Penalty C 6,24 13.00 December 2016 Meclizine Changed from Class 4 to Class 3 6,20 13.00 December 2016 Methapyrilene Changed from Class 4 to Class 3 7,20 13.00 December 2016 Amyl Nitrite Changed from Class 3 to Class 2 1,14 13.00 December 2016 Arformoterol Changed from Penalty A to Penalty B 1,19 13.00 December 2016 Calusterone Changed from Penalty B to Penalty A 2,19 13.00 December 2016 Clostebol Changed from Penalty B to Penalty A 3,19 13.00 December 2016 Dehydrochloromethyltestosterone Changed from Penalty B to Penalty A 3,19 13.00 December 2016 Desoxymethyltestosterone Changed from Penalty B to Penalty A 3,19 13.00 December 2016 Enalapril Changed from Penalty B to Penalty A 4,20 13.00 December 2016 Felbamate Changed from Penalty A to Penalty B 5,20 13.00 December 2016 Furazabol Changed from Penalty B to Penalty A 5,20 13.00 December 2016 Glycopyrrolate Changed from Class 3/Penalty B to Class 4/Penalty C 5,24 13.00 December 2016 Mepenzolate Changed from Penalty A to Penalty B 6,20 13.00 December 2016 Mestanolone Changed from Penalty B to Penalty A 7,20 13.00 December 2016 Mesterolone Changed from Penalty B to Penalty A 7,20 13.00 December 2016 Methandrostenolone (Methandienone) Added alternate name, Changed from Penalty B to Penalty A 7,20 13.00 December 2016 Methandriol (Methylandrostenediol) Added alternate name, Changed from Penalty B to Penalty A 7,20 13.00 December 2016 Metenolone Chagned from Penalty B to Penalty A 7,20 13.00 December 2016 Methyldienolone Changed from Penalty B to Penalty A 7,21 13.00 December 2016 Methylnortestosterone (Trestolone) Added alternate name, Changed from Penalty B to Penalty A 7,21 13.00 December 2016 Methsuximide Changed from Class 3/Penalty A to Class 4/Penalty B 7,24 13.00 December 2016 Methyltestosterone Changed from Penalty B to Penalty A 7,21 13.00 December 2016 Naloxone Changed from Penalty A to Penalty B 8,21 13.00 December 2016 Naltrexone Changed from Penalty A to Penalty B 8,21 13.00 December 2016 N-Butylscopolamine Changed from Class 3/Penalty B to Class 4/Penalty C 2,7,24 13.00 December 2016 Nitroglycerin Changed from Class 3 to Class 2 8,16 13.00 December 2016 Norbolethone/Norboletone Added alternate spelling, Changed from Penalty B to Penalty A 8,21 13.00 December 2016 Norclostebol Changed from Penalty B to Penalty A 8,21 13.00 December 2016 Oxabolone Changed from Penalty B to Penalty A 8,21 13.00 December 2016 Oxprenolol Changed from Penalty B to Penalty A 8,21 13.00 December 2016 Physostigmine Changed from Penalty B to Penalty A 9,21

Page 61 of 66 Approx. Version Date Drug/Substance Notes Page(s) 13.00 December 2016 Pindolol Changed from Penalty A to Penalty B 9,21 13.00 December 2016 Amitraz Changed from Penalty A to Penalty B 1,19 13.00 December 2016 Alprenolol Changed from Class 3 to Class 2 1,14 13.00 December 2016 Zomepirac Changed from Penalty A to Penalty B 11,18 13.00 December 2016 Yohimbine Changed from Penalty A to Penalty B 11,18 13.00 December 2016 Snake Venoms Changed from Class 2 to Class 1 10,13 13.00 December 2016 Romifidine Changed from Class 2 to Class 3 10,21 13.00 December 2016 Rofecoxib Changed from Penalty A to Penalty B 10,17 13.00 December 2016 Reserpine Changed from Penalty A to Penalty B 10,17 13.00 December 2016 Midazolam Changed from Class 2/Penalty A to Class 3/Penalty B 7,21 13.00 December 2016 Loperamide Changed from Class 2/Penalty A to Class 3/Penalty B 6,20 13.00 December 2016 Isoxicam Changed from Penalty A to Penalty B 6,16 13.00 December 2016 Fluphenazine Changed from Penalty A to Penalty B 5,15 13.00 December 2016 Fenclozic Acid Changed from Penalty A to Penalty B 5,15 13.00 December 2016 Erythropoietin Changed from Class 2 to Class 1 4,12 13.00 December 2016 Diazepam Changed from Class 2 to Class 3 4,19 Changed from Class 2 to Class 1; Corrected spelling under Darbepoetin 13.00 December 2016 “Prohibited Practices” vi,3,12 13.00 December 2016 Chlorpromazine Changed from Class 2 to Class 1 3,12 13.00 December 2016 Benoxaprofen Changed from Penalty A to Penalty B 1,14 13.00 December 2016 Alclofenac Changed from Penalty A to Penalty B 1,14 13.00 December 2016 Atipamazole Added to Uniform Classification Guide as Class 2, Penalty B 1,14 13.00 December 2016 Cocaine Changed from Penalty B to Penalty A 3,12 13.00 December 2016 Ethylphenidate Added to Uniform Classification Guide as Class 1, Penalty A 5,12 13.00 December 2016 Meldonium Added to Uniform Classification Guide as Class 1, Penalty A 6,12 13.00 December 2016 Morphine Changed from Penalty B to Penalty A 7,12 13.00 December 2016 Strychnine Changed from Penalty B to Penalty A 10,13 Added footnote language recommending Penalty B if testing can 12.00 March 2016 Methamphetamine prove presence of only levo-methamphetamine is present in sample. 7, 13 12.00 March 2016 Tramadol Changed from Penalty A to Penalty B 11, 19 Changed from Penalty B to Penalty C after inclusion into ARCI 12.00 March 2016 Cetirizine Controlled Therapeutic Medicaion Schedule 2, 24

Page 62 of 66 Approx. Version Date Drug/Substance Notes Page(s) Added footnote language recommending Penalty A if intentional 12.00 March 2016 Morphine 8, 13 administration can be proven by regulators. Added footnote language recommending Penalty A if intentional 12.00 March 2016 Cocaine 3, 13 administration can be proven by regulators. Corrected spelling error in Alphabetical Listing by Substance 12.00 March 2016 Methacholine Section and Listing by Classification Section 7, 20 Corrected spelling error in Alphabetical Listing by Substance 12.00 March 2016 myo-inositol trispyrophosphate (ITPP) Section and Listing by Classification Section 8, 13 Corrected typographical error to reflect Class 4, Penalty B 11.00 December 2015 2-Aminoheptane 1, 23 Substance Corrected typographical error to reflect Class 4, Penalty B 11.00 December 2015 Xylometazoline Substance 11, 25 Corrected typographical error to reflect Class 2, Penalty A 11.00 December 2015 Rivastigmine Substance 10, 17 Corrected typographical error to reflect Class 5, Penalty D 11.00 December 2015 Rabeprazole 10 26 Substance Corrected typographical error to reflect Class 2, Penalty A 11.00 December 2015 Prilocaine 9, 17 Substance Corrected typographical error to reflect Class 4, Penalty B 11.00 December 2015 Hexocyclium 6, 24 Substance Corrected typographical error to reflect Class 3, Penalty B 11.00 December 2015 Gabapentin 5, 20 Substance Corrected typographical error to reflect Class 2, Penalty A 11.00 December 2015 Mesylates 4, 15 Substance Corrected typographical error to reflect Class 4, Penalty B 11.00 December 2015 Butacaine Substance 2, 23 Corrected typographical error to reflect Class 4, Penalty C 11.00 December 2015 Budesonide 2, 23 Substance Corrected typographical error to reflect Class 2, Penalty A 11.00 December 2015 Brimonidine 2, 14 Substance Corrected typographical error to reflect Class 3, Penalty B 11.00 December 2015 Benazepril 2, 19 Substance

Page 63 of 66 Approx. Version Date Drug/Substance Notes Page(s) Corrected typographical error to reflect Class 3, Penalty B 11.00 December 2015 Amlodipine 1, 19 Substance 11.00 December 2015 3-Methoxytyramine Added as Class 2, Penalty A Substance 1, 14 10.00 July 2015 Methylhexanamine Added alternative spelling 7, 13 Gamma Aminobutryic Acid 10.00 July 2015 Added as Class 3, Penalty B Substance 5, 19 (GABA) Added as Class 3, Penalty B with note to refer to ARCI Endogenous, Dietary, or Environmental Substances Schedule for 9.00 April 2015 Cobalt 3, 18 threshold and penalty information for contrations of less than 50 parts per billion (ppb) in blood serum or plasma Changed Penalty Class from “B” to “C” to conform to the ARCI 8.00 December 2014 Firocoxib Controlled Therapeutic Medication Schedule 5, 23 Had been previously omitted from Listing by Classification Section, 8.00 December 2014 Acenocoumarol Added to section 25 8.00 December 2014 Deracoxib Corrected Spelling in Alphabetical Listing by Substance Section 3 8.00 December 2014 Norclostebol Corrected Spelling in Alphabetical Listing by Substance Section 8 8.00 December 2014 Rizatriptan Corrected Spelling in Alphabetical Listing by Substance Section 10 8.00 December 2014 Dehydrochloromethyltestosterone Corrected Spelling in Alphabetical Listing by Substance Section 3 8.00 December 2014 Amiodarone Corrected Spelling in Listing by Classification Section 22 8.00 December 2014 2-Aminoheptane Corrected Spelling in Listing by Classification Section 22 8.00 December 2014 Bupropion Corrected Spelling in Listing by Classification Section 13 8.00 December 2014 Alclofenac Assigned Penalty Class A 1, 13 Updated the recommended penalty for Ketoprofen to comply with Recommended Penalties for 8.00 December 2014 the primary threshold established in the ARCI Controlled 29 Ketoprofen Therapeutic Medication Schedule. Corrected typographical error on recommended penalties for Class B substances for licensed owners. Version 7.00 incorrectly 8.00 December 2014 Class B Recommended Penalties recommended penalties for second or third offense in the owner’s 28 lifetime. Version 8.00 corrects error and recommends penalty for second or third offense in 365-day period. Addition is not a change ot the Uniform Classification Guidelines. 8.00 December 2014 Aminorex 1, 13 Aminorex has been a DEA Schedule 1 substance. All DEA Schedule

Page 64 of 66 Approx. Version Date Drug/Substance Notes Page(s) 1 substances are considered Class 1, Penalty A substances by reference. By request, Aminorex has been listed to avoid confusion. 8.00 December 2014 Bufotenine Corrected the precursor to 5-methoxy-N-N dimethyltryptamine 26 7.00 January 2014 Pergolide Added as Class 3, Penalty B 8, 20 6.00 December 2013 Methylhexaneamine Added as Class 1, Penalty A 7, 12 Moved from Class 3 to Class 2 Substance, Penalty Remains 5.00 December 2012 Zilpaterol hydrochloride 11, 17 Unchanged 5.00 December 2012 Tetramisole hydrochloride Removed from Non-Classified Substance list 26 5.00 December 2012 Ambroxol Moved from Class 4, Penalty B to Class 4, Penalty C 1, 22 Corrected typographical error in Drug Class (Incorrectly listed as a 4.01 October 2012 Ractopamine 9, 16 Class 3 substance) Corrected typographical error on Penalty Class (Listed as Penalty 4.01 October 2012 Pyrilamine Class A in “Listing by Classification” section. 9, 20 myo-inositol trispyrophosphate 4.00 July 2012 (ITPP) Added as Class 1, Penalty A 7, 12 4.00 July 2012 Benzonatate Added as Class 2, Penalty A 2, 13 Corrected Penalty Class omission in Alphabetical Listing section of 3.00 December 2011 Almotriptan 1, 18 document Corrected Penalty Class omission in Alphabetical Listing section of 3.00 December 2011 Naltrexone 7, 20 document Corrected Penalty Class omission in Alphabetical Listing section of 3.00 December 2011 Amiloride 1, 22 document Corrected Penalty Class omission in Alphabetical Listing section of 3.00 December 2011 Butanilicaine document 2, 13 3.00 December 2011 3,4-methylenedioxy-, Corrected typographical error in Trade Name sections 1, 12 aka MDPV, “”

3.00 December 2011 Carbazochrome Added as Class 4, Penalty C 2, 22

Edited Drug Classification definitions to remove mention of DMSO 2.01 August 2011 Dimethylsulfoxide (DMSO) from Class 5 definition vii

Page 65 of 66 Approx. Version Date Drug/Substance Notes Page(s) Language pertaining to all drugs/substances not found in this 2.00 July 2011 <> ii document shall be considered a Class I, Penalty A Substance Penalties for tests over 2.0 micrograms per milliliter of plasma or 2.00 July 2011 Phenylbutazone serum but less than 5.0 micrograms per milliliter of plasma or serum 29 added. 2.00 July 2011 Dermorphin Added as Class 1, Penalty A 3, 12 3,4-methylenedioxy-pyrovalerone, 2.00 July 2011 aka MDPV, “Bath Salts” Added as Class 1, Penalty A 1, 12 2.00 July 2011 Synthetic cannabis Added as Class 1, Penalty A 10, 12 2.00 July 2011 Alclomethasone Corrected typographical error in spelling 1, 22 Corrected typographical error on Penalty Class from Class B to 1.01 January 2011 Methocarbamol Class C 7, 23 1.00 December 2010 Zilpaterol Added as Class 3, Penalty a 11, 17 1.00 December 2010 Dimethylsulfoxide (DMSO) Changed from Class 5 to Class 4 4, 23

Page 66 of 66